Bank of America Corp DE Takes Position in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Bank of America acquired 256,833 shares of Dianthus Therapeutics, worth approximately $25.0 million, giving it a 0.47% stake. Institutional investors and hedge funds collectively own 47.53% of the company.
• DNTH shares fell 5.0% to $93.44, while the company reported a quarterly loss of $0.90 per share, missing the $0.85 consensus estimate. Analysts expect a full-year loss of $3.81 per share.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $129.83. However, insiders have sold 273,678 shares worth roughly $29.3 million over the past 90 days.

Bank of America Corp DE purchased a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 256,833 shares of the company's stock, valued at approximately $25,036,000. Bank of America Corp DE owned approximately 0.47% of Dianthus Therapeutics at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in DNTH. ABS Investment Management LLC acquired a new position in shares of Dianthus Therapeutics in the second quarter worth $194,960,000. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics in the 1st quarter valued at $32,000. EFG International AG acquired a new stake in shares of Dianthus Therapeutics in the second quarter worth about $49,000. Global Retirement Partners LLC acquired a new stake in shares of Dianthus Therapeutics in the second quarter worth about $93,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Dianthus Therapeutics during the 4th quarter worth about $43,000. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Trading Down 5.0%

Shares of DNTH stock opened at $93.44 on Thursday. Dianthus Therapeutics, Inc. has a 1 year low of $32.22 and a 1 year high of $117.88. The firm's fifty day simple moving average is $106.79 and its 200 day simple moving average is $93.87. The firm has a market capitalization of $5.12 billion, a P/E ratio of -22.52 and a beta of 1.24.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on DNTH. HC Wainwright raised their price objective on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. assumed coverage on Dianthus Therapeutics in a research report on Friday, September 11th. They set an "overweight" rating and a $135.00 target price for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. TD Cowen reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Raymond James Financial reiterated a "strong-buy" rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $129.83.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 23,124 shares of the firm's stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total value of $2,460,624.84. Following the completion of the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $425,640. This trade represents a 85.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Ryan Savitz sold 31,249 shares of the company's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the transaction, the executive vice president owned 31,249 shares of the company's stock, valued at $3,157,086.47. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 273,678 shares of company stock worth $29,276,000. 3.02% of the stock is currently owned by company insiders.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.

The company's lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.